Theratechnologies announced the launch of a marketed public offering of common shares of the company. In connection with the offering, the company intends to enter into a subscription agreement with Investissement Quebec for a concurrent private placement of common shares for up to $12.5M aggregate gross proceeds. Cantor Fitzgerald & Co. is acting as the underwriter for the public offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THTX:
- Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
- Theratechnologies announces operational update
- Theratechnologies’ Ibalizumab demonstrates cost-effectiveness
- Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
- Theratechnologies finalizes amendments of credit agreement with Marathon